Early-Career Members Join NMD4C Working Groups
The NMD4C is happy to announce that six early-career network members have been appointed to leadership roles on three NMD4C working groups: Biobanking, Early-Career, and Knowledge Translation.
The network looks forward to the valuable input and broadened perspective that each member has or will provide to these network activities, and would like to welcome the following early-career members to our working groups:
- Drs. Élise Duchesne and Gerald Pfeffer, who have joined the biobanking working group.
- Drs. Natasha Chang and Cam-Tu Nguyen, who have joined the Early-Career working group.
- Drs. Kessen Patten and Mona Hnaini, who have joined the Knowledge Translation working group.
The NMD4C are committed to empowering the next generation of early-career researchers and clinicians in building successful careers in neuromuscular disease research and clinical practice. Providing early-career leadership opportunities within the network will not only amplify the early-career perspective and help to inform the network’s activities, but also empowers our members to become future leaders in the neuromuscular community.
Other opportunities that the NMD4C provides for early-career members include:
- Sharing blog posts from early-career members
- Research and clinical fellowship funding opportunities
- Webinars and events tailored to early-career audience
If you are an early-career researcher or clinician, please feel free to visit our early-career page or contact James Davis at if you are interested in further engagement with the network.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.